Ultimovacs AS Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.04.25	Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider (GlobeNewswire)
04.04.25	Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025 (GlobeNewswire)
02.04.25	Zelluna ASA [ZLNA]: Annual Report 2024 (GlobeNewswire)
01.04.25	Zelluna ASA [ZLNA]: Ex reverse share split today (GlobeNewswire)
31.03.25	Zelluna ASA [ZLNA]: Registration of reverse share split (GlobeNewswire)
27.03.25	Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of ISIN (GlobeNewswire)
27.03.25	Zelluna ASA [ZLNA]: Share capital increase registered (GlobeNewswire)
26.03.25	Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider (GlobeNewswire)
26.03.25	Zelluna ASA [ZLNA]: Share capital increase resolution (GlobeNewswire)
03.03.25	Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement (GlobeNewswire)
28.02.25	Ultimovacs ASA: Approval and publication of prospectus (GlobeNewswire)
13.02.25	Ultimovacs ASA: Cancellation of subsequent repair offering (GlobeNewswire)
31.01.25	Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update (GlobeNewswire)
27.01.25	Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation (GlobeNewswire)
09.01.25	Ultimovacs ASA: Notification of major holdings (GlobeNewswire)
09.01.25	Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025 (GlobeNewswire)
08.01.25	Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting (GlobeNewswire)
06.01.25	Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting (GlobeNewswire)
05.01.25	Ultimovacs ASA: Regarding the extraordinary general meeting on 9 January 2025 (GlobeNewswire)
19.12.24	Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 - CORRECTION (GlobeNewswire)
19.12.24	Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 (GlobeNewswire)
18.12.24	ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY (GlobeNewswire)
17.12.24	Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA (GlobeNewswire)
17.12.24	Ultimovacs ASA – Mandatory notification of trade (GlobeNewswire)
17.12.24	ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT (GlobeNewswire)
06.11.24	Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update (GlobeNewswire)
31.10.24	Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation (GlobeNewswire)
25.10.24	Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv (GlobeNewswire)
11.09.24	Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer (GlobeNewswire)
09.09.24	Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 (GlobeNewswire)
21.08.24	Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update (GlobeNewswire)
15.08.24	Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation (GlobeNewswire)
07.08.24	Ultimovacs Announces Notice of Resignation from Deputy Board Member (GlobeNewswire)
05.08.24	Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer (GlobeNewswire)
01.08.24	Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 (GlobeNewswire)
24.06.24	Ultimovacs ASA announces revised terms of the employee share option program (GlobeNewswire)
11.06.24	Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab (GlobeNewswire)
01.06.24	Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
07.05.24	Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update (GlobeNewswire)
30.04.24	Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation (GlobeNewswire)
24.04.24	Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
18.04.24	Ultimovacs ASA – Annual General Meeting held on April 18, 2024 (GlobeNewswire)
16.04.24	Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program (GlobeNewswire)
15.04.24	Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting (GlobeNewswire)
09.04.24	Ultimovacs – Invitation to Business Update on April 17, 2024 (GlobeNewswire)
04.04.24	Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
25.03.24	Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024 (GlobeNewswire)
22.03.24	Ultimovacs ASA: Mandatory notification of trade by primary insider (GlobeNewswire)
21.03.24	Ultimovacs ASA: Annual Report 2023 (GlobeNewswire)
09.03.24	Ultimovacs ASA: Mandatory notification of trades by primary insider (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swiss Re	151.05	1.48 %	K V
Swiss Life Hldg	841.60	1.03 %	K V
Zurich Insur Gr	591.40	0.92 %	K V
Geberit	587.40	0.79 %	K V
UBS Group	25.45	0.63 %	K V
Swisscom	545.50	-0.46 %	K V
Sika	208.20	-0.53 %	K V
Alcon	80.68	-0.62 %	K V
CieFinRichemont	145.40	-0.82 %	K V
Novartis	92.93	-1.36 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Ultimovacs AS Registered Shs Aktie VALOR 48073435 / ISIN NO0010851603

Nachrichten zu Ultimovacs AS Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten